- Highly statistically significant and clinically meaningful results -
- 63% mean blood Phe reduction in primary analysis population (p
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
On 6ix: 6ix.com/news/ptc-therapeutics-announces-aphenity-trial-achieved-primary-endpoint-with-sepiapterin
Watch PTC Therapeutics' latest callPTC Therapeutics (NASDAQ:PTCT) Q3 2026 Earnings Call · Replay · Oct 29Read the transcript of PTC Therapeutics (NASDAQ:PTCT) Q3 2026 Earnings CallIn the deck
Earlier from PTC Therapeutics
- PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
- Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
- PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Later from PTC Therapeutics
- PTC Therapeutics Announces Strategic Pipeline Prioritization
- PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
- PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
- PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
- PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
Follow PTC Therapeutics into a list and get an email when it puts out news.
Follow PTC Therapeutics